by Mark Curtis | Nov 19, 2013
. Welcome to October’s Update from the Clinic. Interesting developments this past month included the release of Phase 1/2a data from Living Cell Technologies that provides a first look at the safety and efficacy of its DIABECELL® product. We also saw an approval for...
by David Kent | Jun 27, 2013
. Last week I was forwarded a Cell Stem Cell article to consider by another Signals blogger entitled, “Dear Student: Stem Cell Scientists’ Advice to the Next Generation.” As a stem cell biologist still in training, I was curious to read what senior established stem...
by Paul Krzyzanowski | Jun 6, 2013
GMO soybeans might have lessons for cell patents. Photo: Philip Dean via Flickr . At first glance, you wouldn’t think that a 76-year old soybean farmer from Indiana would have something in common with microbiologists, but Vernon Hugh Bowman brought back memories of my...
by David Kent | May 28, 2013
. A few weeks ago, Italian private company Stamina came under considerable pressure regarding their controversial use of mesenchymal stem cells in patients. The Italian government, it seems, had authorized an unproven stem cell therapy for use in patients. The...
by Lisa Willemse | May 24, 2013
Co-authored with Dr. Zubin Master, Assistant Professor at the Alden March Bioethics Institute, Albany Medical College and Research Associate at the University of Alberta’s Health Law and Science Policy Group. In the current discussion about the now controversial...
by Lisa Willemse | Apr 25, 2013
Co-authored with Geoff Lomax, CIRM’s Senior Officer to the Standards Working Group from the “Understanding Stem Cell Controversies” Workshop organized by the Stem Cell Network in Montreal. This article is cross-posted on the CIRM blog. The afternoon session on Day 2...
Comments